Bvf Inc Chemo Centryx, Inc. Transaction History

Bvf Inc

$3.15 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2019 Feb 14, 2020	SELL	$6.81 - $39.55 $9.63 Million - $55.9 Million	-1,414,515 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $415,500 - $742,500	-50,000 Reduced 3.41%	1,414,515 $13.2 Million
Q1 2019 May 15, 2019	SELL	$10.01 - $13.89 $52.3 Million - $72.5 Million	-5,223,008 Reduced 78.1%	1,464,515 $20.3 Million
Q4 2018 Feb 14, 2019	SELL	$9.15 - $12.26 $789,068 - $1.06 Million	-86,237 Reduced 1.27%	6,687,523 $73 Million
Q3 2018 Nov 14, 2018	SELL	$10.49 - $13.72 $2.73 Million - $3.58 Million	-260,586 Reduced 3.7%	6,773,760 $85.6 Million
Q2 2018 Aug 14, 2018	SELL	$10.62 - $13.98 $1.77 Million - $2.33 Million	-166,970 Reduced 2.32%	7,034,346 $92.6 Million
Q1 2018 May 07, 2018	SELL	$5.9 - $14.99 $2.28 Million - $5.79 Million	-386,100 Reduced 5.09%	7,201,316 $97.9 Million
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $49.3 Million - $81.1 Million	7,587,416	7,587,416 $56.3 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.